DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+19.48%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$161M
AUM Growth
+$161M
(+15%)
Cap. Flow
-$3.12M
Cap. Flow
% of AUM
-1.94%
Top 10 Holdings %
Top 10 Hldgs %
48.45%
Holding
88
New
12
Increased
11
Reduced
19
Closed
15
Top Buys
| 1 |
CBAY
Cymabay Therapeutics
CBAY
|
$3.35M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
$3.16M |
| 3 |
DexCom
DXCM
|
$2.81M |
| 4 |
ACHN
Achillion Pharmaceuticals, Inc.
ACHN
|
$2.03M |
| 5 |
Kura Oncology
KURA
|
$1.58M |
Top Sells
| 1 |
LOXO
Loxo Oncology, Inc
LOXO
|
$3.82M |
| 2 |
IMMU
Immunomedics Inc
IMMU
|
$2.48M |
| 3 |
SPNC
Spectranetics Corp
SPNC
|
$2.15M |
| 4 |
Sangamo Therapeutics
SGMO
|
$1.98M |
| 5 |
CLLS
Cellectis
CLLS
|
$1.97M |
Sector Composition
| 1 | Healthcare | 80.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
| $24.1M | 14.99% | 262,121 -41,500 | -14% | -$3.82M |
|
2
AtriCure
ATRC
$1.84B
| $8.59M | 5.34% | 384,145 | – | – |
|
|
ONC
3
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $7.43M | 4.62% | 71,849 -1,187 | -2% | -$123K |
|
|
IMMU
4
DELISTED
Immunomedics Inc
IMMU
| $6.44M | 4% | 460,451 -177,249 | -28% | -$2.48M |
|
|
5
BioCryst Pharmaceuticals
BCRX
$1.74B
| $6.25M | 3.88% | 1,193,228 +602,100 | +102% | +$3.16M |
|
|
NXTM
6
DELISTED
NxStage Medical Inc.
NXTM
| $5.97M | 3.7% | 216,119 | – | – |
|
|
AERI
7
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $5.68M | 3.52% | 116,770 +10,000 | +9% | +$486K |
|
|
BPMC
8
DELISTED
Blueprint Medicines
BPMC
| $5.3M | 3.29% | 76,000 -6,000 | -7% | -$418K |
|
|
ALDR
9
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $4.24M | 2.63% | 346,013 +125,000 | +57% | +$1.53M |
|
|
CBAY
10
DELISTED
Cymabay Therapeutics
CBAY
| $3.51M | 2.18% | 435,000 +415,933 | +2,181% | +$3.35M |
|
11
Neurocrine Biosciences
NBIX
$13.8B
| $3.34M | 2.07% | 54,508 | – | – |
|
|
ACHN
12
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $3.23M | 2% | 718,272 +451,772 | +170% | +$2.03M |
|
13
Galapagos
GLPG
$2.07B
| $3.22M | 2% | 31,609 -7,000 | -18% | -$712K |
|
14
Insulet
PODD
$23.9B
| $3.17M | 1.97% | 57,484 -6,000 | -9% | -$330K |
|
15
iShares Biotechnology ETF
IBB
$5.6B
| $2.9M | 1.8% | 8,700 | – | – |
|
16
MacroGenics
MGNX
$112M
| $2.85M | 1.77% | 154,200 +35,000 | +29% | +$647K |
|
|
17
DexCom
DXCM
$29.5B
| $2.81M | 1.75% | +57,500 | New | +$2.81M |
|
18
Akebia Therapeutics
AKBA
$833M
| $2.67M | 1.66% | 135,738 | – | – |
|
19
Ascendis Pharma
ASND
$11.8B
| $2.62M | 1.63% | 72,226 +39,012 | +117% | +$1.41M |
|
20
Voyager Therapeutics
VYGR
$186M
| $2.41M | 1.5% | 117,259 -87,549 | -43% | -$1.8M |
|
|
RDUS
21
DELISTED
Radius Health, Inc.
RDUS
| $2.06M | 1.28% | 53,309 | – | – |
|
|
DERM
22
DELISTED
Dermira, Inc.
DERM
| $2.04M | 1.27% | 75,500 | – | – |
|
|
ZGNX
23
DELISTED
Zogenix, Inc.
ZGNX
| $1.84M | 1.14% | 52,500 -3,309 | -6% | -$116K |
|
24
Ardelyx
ARDX
$1.53B
| $1.82M | 1.13% | 325,409 -48,000 | -13% | -$269K |
|
25
Spyre Therapeutics
SYRE
$996M
| $1.72M | 1.07% | 349,592 | – | – |
|